Tech Center 1600 • Art Units: 1642 1643 1644
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17520590 | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII | Non-Final OA | Xencor, Inc. |
| 17773283 | DEGRADATION OF SURFACE PROTEINS USING BISPECIFIC BINDING AGENT | Final Rejection | The Regents of the University of California |
| 18032012 | SYNTHETIC ANTIGENS AS CHIMERIC ANTIGEN RECEPTOR (CAR) LIGANDS AND USES THEREOF | Non-Final OA | Georgia Tech Research Corporation |
| 18066529 | PROTEASE-ACTIVATED T CELL BISPECIFIC ANTIBODIES | Non-Final OA | Hoffmann-La Roche Inc. |
| 17927529 | BISPECIFIC MOLECULES FOR SELECTIVELY MODULATING T CELLS | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 16970930 | UNIVERSAL ANTIGEN PRESENTING CELLS AND USES THEREOF | Non-Final OA | Board of Regents, The University of Texas System |
| 18034026 | METHODS OF TREATING INFECTIONS BY BLOCKING PATHOGEN MIMICS OF CD47 | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17997161 | TREATMENT AND PREVENTION OF CANCER USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | Final Rejection | Baylor College of Medicine |
| 17765585 | METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES | Non-Final OA | ASTRAZENECA AB |
| 18249149 | SPECIFIC TARGETING OF TUMOR-INFILTRATING REGULATORY T CELLS (TREGS) USING ICOS AND IL-1R | Non-Final OA | FRED HUTCHINSON CANCER CENTER |
| 18326335 | ANTI-BMP9 ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | The General Hospital Corporation |
| 17777659 | STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY | Non-Final OA | Children's Medical Center Corporation |
| 18008278 | Improved T cell receptor-costimulatory molecule chimera | Non-Final OA | TSINGHUA UNIVERSITY |
| 18010910 | UNIVERSAL CAR-NK CELL TARGETING VARIOUS EPITOPES OF HIV-1 GP160 | Non-Final OA | University of Southern California |
| 18451671 | DETECTION OF ACUTE MYELOID LEUKAEMIA | Non-Final OA | OXFORD UNIVERSITY INNOVATION LIMITED |
| 18007290 | METHODS TO STIMULATE IMMUNE RESPONSES TO MUTANT RAS USING ANUCLEATE CELLS | Non-Final OA | STEMCELL TECHNOLOGIES CANADA INC. |
| 17787094 | MULTI-SPECIFIC ANTIBODIES | Final Rejection | UCB BIOPHARMA SRL |
| 17630601 | METHODS FOR TREATMENT OF REFRACTORY GENERALIZED MYASTHENIA GRAVIS WITH ECULIZUMAB | Final Rejection | Alexion Pharmaceuticals, Inc. |
| 17770304 | Immunotherapy Targeting Tumor Neoantigenic Peptides | Non-Final OA | INSERM (Institut National de la Santé et de la Recherche Médicale) |
| 17830865 | PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF | Final Rejection | Sorrento Therapeutics, Inc. |
| 18285636 | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING THE SAME | Non-Final OA | GC CELL CORPORATION |
| 18285634 | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-CD19 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING THE SAME | Non-Final OA | GC Cell Corporation |
| 18272329 | COMPOSITIONS AND METHODS FOR PREVENTING TUMORS AND CANCER | Non-Final OA | Cancer Advances Inc. |
| 18256172 | ANTIBODY SPECIFIC FOR CD47 AND USES THEREOF | Non-Final OA | INNOBATION BIO., LTD. |
| 18039868 | MODIFIED T CELLS FOR ADOPTIVE IMMUNOTHERAPY | Non-Final OA | GUIZHOU SINORDA BIOTECHNOLOGY CO., LTD. |
| 18167529 | METHODS OF USING INTERLEUKIN-2 AGENTS | Final Rejection | VISTERRA, INC. |
| 18050411 | METHODS FOR CULTURING CELLS EXPRESSING ROR1-BINDING PROTEIN | Non-Final OA | Lyell Immunopharma, Inc. |
| 18113399 | ACTIVATABLE IL-18 POLYPEPTIDES | Final Rejection | Bright Peak Therapeutics AG |
| 18160886 | ANTI-PVRIG PROTEIN ANTIBODY OR ANTIBODY FRAGMENT AND USE THEREOF | Non-Final OA | HEFEI TG IMMUNOPHARMA CO., LTD. |
| 18010974 | COMPOSITIONS AND METHODS FOR MODULATING FLRT3 MEDIATED SIGNAL TRANSDUCTION | Non-Final OA | NEXTCURE, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy